20Dec 2023
Net Clinical Benefit of Oral Anticoagulants in Atrial Fibrillation Patients Based on CHA2DS2-VASc Score

Net Clinical Benefit of Oral Anticoagulants in Atrial Fibrillation Patients Based on CHA2DS2-VASc Score

A prospective study analyzed 3,402 atrial fibrillation (AF) patients from the COOL AF Thailand registry (2014–2017) to assess the net clinical benefit (NCB) of oral anticoagulants (OACs) according to CHA2DS2-VASc score. The study revealed that AF patients with a CHA2DS2-VASc score of 3 or more, whether on warfarin or direct oral anticoagulants (DOACs), demonstrated a positive NCB. Notably, DOACs exhibited a more favorable NCB compared to warfarin, and females showed a higher NCB than males, emphasizing gender and OAC-type variations in treatment outcomes.

  • #cardiology

Like

Save

Share